Engelmann, Cornelius and Sterneck, Martina and Weiss, Karl Heinz and Templin, Silke and Zopf, Steffen and Denk, Gerald and Eurich, Dennis and Pratschke, Johann and Weiss, Johannes and Braun, Felix and Welker, Martin-Walter and Zimmermann, Tim and Knipper, Petra and Nierhoff, Dirk and Lorf, Thomas and Jaeckel, Elmar and Hau, Hans-Michael and Tsui, Tung Yu and Perrakis, Aristoteles and Schlitt, Hans-Juergen and Herzer, Kerstin and Tacke, Frank (2020) Prevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers. JOURNAL OF CLINICAL MEDICINE, 9 (8): 2352. ISSN , 2077-0383
Full text not available from this repository. (Request a copy)Abstract
Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in liver transplant recipients, but their toxicity needs to be balanced against the benefits. The choice of prevention strategy (prophylaxis or preemptive treatment) depends on the donor/recipient sero-status but may vary between institutions. We conducted a series of consultations and roundtable discussions with German liver transplant center representatives. Based on 20 out of 22 centers, we herein summarize the current approaches to CMV prevention and treatment in the context of liver transplantation in Germany. In 90% of centers, transient prophylaxis with ganciclovir or valganciclovir was standard of care in high-risk (donor CMV positive, recipient CMV naive) settings, while preemptive therapy (based on CMV viremia detected during (bi) weekly PCR testing for circulating CMV-DNA) was preferred in moderate- and low-risk settings. Duration of prophylaxis or intense surveillance was 3-6 months. In the case of CMV infection, immunosuppression was adapted. In most centers, antiviral treatment was initiated based on PCR results (median threshold value of 1000 copies/mL) with or without symptoms. Therefore, German transplant centers report similar approaches to the prevention and management of CMV infection in liver transplantation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | VALGANCICLOVIR CYTOMEGALOVIRUS PROPHYLAXIS; INTERNATIONAL CONSENSUS GUIDELINES; DRUG-RESISTANT CYTOMEGALOVIRUS; PREEMPTIVE THERAPY; CLINICAL UTILITY; INTRAVENOUS GANCICLOVIR; ANTIVIRAL PROPHYLAXIS; ANTIGENEMIA ASSAY; ORAL GANCICLOVIR; DISEASE; OLT; ganciclovir; valganciclovir; mTOR inhibitor |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 17 Mar 2021 09:43 |
| Last Modified: | 17 Mar 2021 09:43 |
| URI: | https://pred.uni-regensburg.de/id/eprint/44077 |
Actions (login required)
 |
View Item |
